Medicus Pharma (MDCX) Net Income towards Common Stockholders (2024 - 2025)

Medicus Pharma (MDCX) posted Net Income towards Common Stockholders of -$15.1 million for Q4 2025, down 100448813.33% quarter-over-quarter from -$15.0 in Q3 2025, and down 326.05% year-on-year from $6.7 million in Q4 2024.

Medicus Pharma (MDCX) Net Income towards Common Stockholders (2024 - 2025) Analysis & Trends

Medicus Pharma (MDCX) has reported Net Income towards Common Stockholders for 2 consecutive years, with -$15.1 million the latest figure, recorded in Q4 2025.

  • Net Income towards Common Stockholders for Q4 2025 came in at -$15.1 million, down 326.05% year-over-year; the trailing twelve-month figure through Dec 2025 was -$26.2 million (down 136.41% YoY), and the FY2025 annual result was -$47.3 million, down 323.84% from the prior year.
  • Net Income towards Common Stockholders was -$15.1 million for Q4 2025 at Medicus Pharma, down from -$15.0 in the prior quarter.
  • Over five years, Net Income towards Common Stockholders peaked at -$15.0 in Q3 2025 and troughed at -$15.1 million in Q4 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn 7.40 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn 5.24 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn 697.00 Mn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn 47.33 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn -4.21 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn 1.82 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn 2.02 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn -13.00 Mn
9 Novartis Ag 113.45 Bn 113.67 Bn - 1.65
10 Medicus Pharma 6.91 Mn -1.69 Mn - -15.07 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 -15.07 Mn
Sep 30, 2025 -15.00
Jun 30, 2025 -6.02 Mn
Mar 31, 2025 -5.10 Mn
Dec 31, 2024 -3.54 Mn
Sep 30, 2024 -2.28 Mn
Jun 30, 2024 -3.55 Mn
Mar 31, 2024 -1.71 Mn